	PTO/SB/08A (10/01) (modified) U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE											
Substitu	te for	form 1449/	VPTO	E WILL	Je je	Appli	cation Number	10/762,388				
INFORMATION DISCE					MARKE	Filing Date		January 22, 2004				
First Named Inventor   Lames   Madara							·					
STATEMENT BY APPLICANT (use as many sheets as necessary)  Art Unit  Unknown												
	(us	e as many	SHEELS	as necessar	יע	Examiner Name		Unknown				
Sheet	T	1	of	4		Attori	ney Docket Number	7210.03				
U.S. PATENT DOCUMENTS												
*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)			Publication Date MM-DD-YYYY		Pages, ( Name of Patentee or Rele		Relevant P	lumns, Lines, Where ant Passages or nt Figures Appear		
26			,441,951		8-1995		Serhan					
2-5			,648,512		7-1997		Serhan					
5.6		US- 6,353,026			3-2002	2002 Serhan				,		
2.		US- 6,458,839			10-2002		Madara et al.					
2-6		US- 6,699,905			3-2004	; 11.	Madara et al.					
		US-										
				FC	DREIGN P	PATEN	IT DOCUMENTS	T		<u> </u>		
		FOREIGN	PATENT	DOCUMENT								
*Examiner	Cite	Country		r - Kind Code	Publication D	Date Name of Patentee or		Pages, Columns, Lines,		TRANSLATION		
Initiat	No.	Code: (if known)			MM-DD-YYYY		pplicant of Cited Document	Where Relevant Passages or Relevant Figures Appear		YES	NO	
Z. (-		PCT WO 94/29262			12-1994							
Zif					1-1995							
2-6		PCT	WO 00	)/54767	9-2000							
'												
		ОТ	HER [	OCUMEN	ITS - NON	I-PAT	ENT LITERATURI	E DOCUM	ENTS			
*Examiner	Ctte	In	clude nam	ne of the author	(in CAPITAL L	ETTERS	), title of the article (when a	opropriate), title	of the	TRANSLA	TION	
Initials	No.			numb	er(s), publisher	city and	Vor country where published	og, etc.), date, page(s), volume-issue try where published  YES				
2.6		Weissmann, G., Smolen, J. E., and Korchak, H. M. (1980) Release of inflammatory mediators from stimulated neutrophils. N. Engl. J. Med. 303, 27-34										
2.6		Serhan, C. N., Haeggstrom, J. Z., and Leslie, C. C. (1996) Lipid mediator networks in cell signaling: update and impact of cytokines. <i>FASEB J.</i> 10, 1147-1158										
2.6		Weiss, S	. J. (198	9) Tissue de	struction by	neutro	neutrophils. N. Engl. J. Med. 320, 365-376				Ċ	
7.6		Serhan, C. N. (1994) Lipoxin biosynthesis and its impact in inflammatory and vascular events.  Biochim. Biophys. Acta 1212, 1-25										

 $\mathcal{E}(x,y_1,y_2)$ 

Borgeat, P., and Naccache, P. H. (1990) Biosynthesis and biological activity of leukotriene B<sub>4</sub>. Clin. Biochem. 23, 459-468

Substitute for form 1449A/PTO **Application Number** 10/762.388 **Filing Date** January 22, 2004 INFORMATION DISCLOSURE First Named Inventor James L. Madara STATEMENT BY APPLICANT Art Unit Unknown (use as many sheets as necessary) **Examiner Name** Unknown **Sheet** 2 of 4 **Attorney Docket Number** 7210.03 OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS Yokomizo, T., Izumi, T., Chang, K., Takuwa, T., and Shimizu, T. (1997) A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387, 620-624 Fiore, S., Romano, M., Reardon, E. M., and Serhan, C. N. (1993) Induction of functional lipoxin A4 receptors in HL-60 cells. *Blood* 81, 3395-3403 Isakson, P., Seibert, K., Masferrer, J., Salvemini, D., Lee, L., and Needleman, P. (1995) Discovery of a better aspirin. Advances in Prostaglandin, Thromboxane & Leukotriene Research П 23. 49-54 Chiang, N., Takano, T., Clish, C. B., Petasis, N. A., Tai, H.-H., and Serhan, C. N. (1998) Aspirintriggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA, ELISA. J. Pharmacol Exper. Ther. 287, 779-Serhan, C. N., Maddox, J. F., Petasis, N. A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H. R., Colgan, S. P., and Madara, J. L. (1995) Design of lipoxin A<sub>4</sub> stable analogs that block П transmigration and adhesion of human neutrophils. Biochemistry 34, 14609-14615 Takano, T., Fiore, S., Maddox, J. F., Brady, H. R., Petasis, N. A., and Serhan, C. N. (1997) Zul Aspirin-triggered 15-epi-lipoxin A<sub>4</sub> (LXA<sub>4</sub>) and LXA<sub>4</sub> Stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. J. Exp. Med. 185, 1693-1704 Owman, C., Garzino-Demo, A., Cocchi, F., Popovic, M., Sabirsh, A., and Gallo, R. (1998) The leukotriene B4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. Proc. Natl. Acad. Sci. 95, 9530-9534 Marcus, A. J. (1995) Aspirin as prophylaxis against colorectal cancer. N. Engl. J. Med. 333, 656-658 Vainio, H., and Morgan, G. (1997) Aspirin for the second hundred years: new uses for an old drug. Pharmacol Toxicol 81, 151-152 Herschman, H. R. (1998) Recent progress in the cellular and molecular biology of prostaglandin Zr.F synthesis. Trends in Cardiovasc. Med. 8, 145-150 П Takano, T., Clish, C. B., Gronert, K., Petasis, N., and Serhan, C. N. (1998) Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A<sub>4</sub> and novel lipoxin B<sub>4</sub> stable analogues. J. Clin. Invest. 101, 819-826 Billah, M. M., Eckel, S., Mullmann, T. J., Egan, R. W., and Siegel, M. I. (1989) Phosphatidylcholine hydrolysis by phospholipase D determines phosphatidate and diglyceride levels in chemotactic peptide-stimulated human neutrophils. Involvement of phsophatidate phosphohydrolase in signal transduction. J. Biol. Chem. 264, 17069-17077 Wakelam, M. J. O., Martin, A., Hodgkin, M. N., Brown, F., Pettit, T. R., Cross, M. J., De Takats, 20 P. G., and Reynolds, J. L. (1997) Role and regulation of phospholipase D activity in normal and cancer cells. Advances in Enzyme Regulation 37, 29-34

S -- 1

		-			<del></del>						
Substitute for form 1449A/PTO					Application Number	10/762,388					
INFORMATION DISCLOSURE				ISCI OSUBE	Filing Date	January 22, 2004					
STATEMENT BY APPLICANT (use as many sheets as necessary)					First Named Inventor	James L. Madara					
					Art Unit	Unknown					
					Examiner Name	Unknown					
Sheet		3	of	4	Attorney Docket Number	7210.03	7210.03				
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS											
Zif		Olson, S. human ne	C., and eutroph	d Lambeth, J. D. (1996) ils. <i>Chem. Phys. Lipids</i> 8	Biochemistry and cell biology 30, 3-19						
2,5		Steed, P. PLD2 and	M., Cla	ark, K. L., Boyar, W. C., nalysis of PLD isoform sp	and Lasala, D. J. (1998) Char plice variants. <i>FASEB J.</i> 12, 1	acterization of human 309-1317					
24		Martin, A. Wakelam <i>Trans.</i> 25	, M. J. (	<ol> <li>(1997) Role and regu</li> </ol>	Brown, F. D., Pettit, T. R., Arr lation of phospholipase D sigr	nstrong, S., and nalling. <i>Biochem. Soc</i> .					
25		Levy, B. C signalling	Levy, B. D., Petasis, N. A., and Serhan, C. N. (1997) Polyisoprenyl phosphates in intracellular signalling. <i>Nature</i> 389, 985-989								
2 f		Agwu, D. E., McPhail, L. C., Sozzani, S., Bass, D. A., and McCall, C. E. (1991) Phosphatidic acid as a second messenger in human polymorphonuclear leukocytes. Effects on activation of NADPH oxidase. <i>J. Clin. Invest.</i> 88, 531-539									
z.f		Pettit, T. R., Martin, A., Horton, T., Liossis, C., Lord, J. M., and Wakelam, M. J. O. (1997) Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions. <i>J. Biol. Chem.</i> 272, 17354-17359									
Zuf		Gomez-Cambronero, J. (1995) Immunoprecipitation of a phospholipase D activity with antiphosphotyrosine antibodies. <i>J. Interferon Cytokine Res.</i> 15, 877-885									
2.6		Abousalham, A., Riviere, M., Teissere, M., and Verger, R. (1993) Improved purification and biochemical characterization of phospholipase D from cabbage. <i>Biochim. Biophys. Acta</i> 1158, 1-7									
'2f		Zhou, HL., Chabot-Fletcher, M., Foley, J. J., Sarau, H. M., Tzimas, M. N., Winkler, J. D., and Torphy, T. J. (1993) Association between leukotriene B₄-induced phospholipase D activation and degranulation of human neutrophils. <i>Biochem. Pharmacol.</i> 46, 139-148									
24		Shechter, I., Fogelman, A. M., and Popjak, G. (1980) A deficiency of mixed function oxidase activities in the cholesterol biosynthetic pathway of human granulocytes. <i>J. Lipid Res.</i> 21, 277-283									
2.5		Rabinowitz, J. L., Baker, D. G., Villanueva, T. G., Asanza, A. P., and Capuzzi, D. M. (1992) Liver lipid profiles of adults taking therapeutic doses of aspirin. <i>Lipids</i> 27, 311-314									
7:5		Claria, J., and Serhan, C. N. (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. <i>Proc. Natl. Acad. Sci.</i> 92, 9475-9479									
5.6		Serhan, C. N. (1997) Lipoxins and Novel Aspirin-Triggered 15-epi-Lipoxins: A Jungle of Cell-Cell Interactions or a Therapeutic Opportunity? <i>Prostaglandins</i> 53, 107-137									
Zif		Exton, J. I	H. (199	7) New developments in	phospholipase D. J. Biol. Ch	em. 272, 15579-15582					
2.6	_	Fensome, A., Whatmore, J., Morgan, C., Jones, D., and Cockcroft, S. (1998) ADP-ribosylation factor and Rho proteins mediate fMLP-dependent activation of phospholipase D in human neutrophils. <i>J. Biol. Chem.</i> 273, 13157-13164									

Substitute for form 1449A/PTO					Application Number	10/762,388					
INFORMATION DISCLOSURE					Filing Date	January 22, 2004	January 22, 2004				
				APPLICANT	First Named Inventor	James L. Madara					
		.IVI⊑IN I ny sheets a:			Art Unit:	Unknown					
(use as	) IIIai	ly silecis a	5 116663	ssary)	Examiner Name	Unknown					
Sheet	$\Box$	4	of	4	Attorney Docket Number	7210.03	7210.03				
OTHE	RD	OCUME	NTS -	NON-PATENT LITE	RATURE DOCUMENTS	3					
26		squalene.	. Evider	nce for a tertiary cyclopro	D. H., and Poulter, C. D. (1996 opylcarbinyl cationic intermed J. Amer. Chem. Soc. 118, 13	liate in the rearrangement					
2.5		Bach, T. J 191-202	Bach, T. J. (1995) Some new aspects of isoprenoid biosynthesis in plantsa review. Lipids 30,								
205		Serhan et al., "Aspirin-Triggered 15-EPI-Lipoxin A <sub>4</sub> and Novel Lipoxin B <sub>4</sub> Stable Analogs Inhibit Neutrophil-Mediated Changes in Vascular Permeability," <i>Advances in Experimental Medicine and Biology</i> , Vol. 469, 1999, pgs. 287-293									
Zif		Gewirzt et al., "Pathogen-Induced Chemokine Secretion from Model Intestinal Epithelium is Inhibited by Lipoxin A₄ Analogs", <i>Journal of Clinical Investigation</i> , Vol. 101, No. 9, May 1998, pgs. 1860-1869									
Zuf		Hansson et al., "Activation of Protein Kinase C By Lipoxin A and Other Eicosandoids. Intracellular Action of Oxygenation Products of Arachidonic Acid", <i>Biochemical and Biophysical Research Communications</i> , Vol. 134, No. 3, 1986, pgs. 1215-1222									
2.4		Olson et al., "Biochemistry and cell biology of phospholipase D in human neutrophils", Chemistry and Physics of Lipids, 80, pp. 3-19, 1996									
24	-	Takano et al., "Neutrophil-mediated Changes in Vascular Permeability Are Inhibited by Topical Application of Aspirin-triggered 15-epi-lipoxin A <sub>4</sub> and Novel Lipoxin B <sub>4</sub> Stable Analogues", J. Clin. Invest. Volume 101, Number 4, February 1998, pp. 819-826									
•	:										
EXAMIN	NER :	SIGNATURI	E Z	Eabout F	DATE CONSIDERED	8/20/05		-			
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through										

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

6iPE	
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	DTO/DD/DA (40/04) (
1 5 2001 S	PTO/SB/08A (10/01) (modified) U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute fortierm 1449A/PTO						Appli	cation Number	10/762,388						
						Filing	Date	January 22, 2004						
INFORMATION DISCLOSURE						First	Named Inventor	James L. Madara						
STATEMENT BY APPLICANT						Art U	nit	1614						
(use as many sheets as necessary)							niner Name	Unknown						
Sheet	$\top$	1	of	1		Attor	Attorney Docket Number 7210.03							
				<u></u>	U.S. PAT	ENT I	ENT DOCUMENTS							
*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)			Publication MM-DD-Y	n Date Name of Patentee				t Passages or				
		US-			<u> </u>				-					
		US-												
		UŞ-												
		US-			ļ					<del> </del>				
		US-												
		US-												
		US-												
		US-			-									
		US-												
		US-			<u> </u>									
		US-							<del>- :</del>					
		US-			<u> </u>									
		US-												
		US-			<u> </u>		<u> </u>							
<del> </del>	<del>,                                    </del>			FC	<u>PEIGN P</u>	ATEN	T DOCUMENTS	т						
*Examiner	Cite	FOREIGI Country Code:		T DOCUMENT er - Kind Code (if known)	Publication Date	on	Name of Patentee or	Pages, Co Where Rele	Pages, Columns, Lines, Where Relevant Passages		TRANSLATION			
Initial	No.				MM-DD-Y		Applicant of Cited Document		Figures Appear	YES	NO			
200		JP	63-178	325 	01-28-19	88 T	Геijin Ltd.							
							· · · · · · · · · · · · · · · · · · ·							
				<del></del>										
								·						
					T	$^{-}\bot$								
EXAMI	EXAMINER SIGNATURE Zahlfay DATE CONSIDERED 8/20/05													
*57444		. Initial if					tation is in conformance	- WALL	2 000 0 1	· 4 ·				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.